Two different medicines share the word ketamine, and your health plan does not treat them the same way. Is ketamine therapy covered by insurance? Sometimes. What decides it is which form your psychiatrist recommends, because one carries an FDA approval and one is used off-label.
Spravato, the esketamine nasal spray, is approved for treatment-resistant depression and moves through a real benefits pathway. Ketamine itself does not hold that approval for depression. Clinicians may still use it, and many do, but plans rarely pay for it.
Here is where we stand, stated plainly. Washington Behavioral Medicine Associates is an out-of-network practice, and we do not bill insurance directly. Spravato is the exception worth knowing about, because it can still run through your plan at BMS.care, our affiliated in-network practice. You get ketamine and Spravato under one psychiatric team here, and ketamine is self-pay, given as an intramuscular injection.
So this page answers the money questions in the order patients actually ask them. What each form costs when nobody but you is paying. What plans require before they will approve Spravato. Which route still runs through insurance, and which questions to ask your insurer before you book anything.
Why Insurance Treats Spravato and Ketamine Differently
Coverage follows FDA approval. That is the whole reason these two treatments diverge on your bill, and nearly every other difference in cost traces back to that one fact. Grasp the approval difference and the rest of the insurance picture stops feeling arbitrary. It is the thing worth understanding before you call your plan.
The current label approves Spravato for treatment-resistant depression in adults, either as a standalone treatment or alongside an oral antidepressant. It separately covers depressive symptoms in adults with major depressive disorder who have acute suicidal thoughts or actions. The standalone option is recent, approved by the FDA in January 2025.
The same label sets the conditions plans price against. Spravato is available only through a restricted program called the SPRAVATO REMS, and patients must be monitored by a healthcare provider for at least two hours after every dose. The full FDA label for Spravato carries the primary text if you want to read it yourself.
Ketamine itself sits somewhere else entirely. It is a generic anesthetic used off-label for depression, and the route does not change that. Infusion, intramuscular injection, lozenge, the FDA has not approved any of them for depression. Off-label prescribing is legal and routine across medicine, but plans generally decline to pay for it, which is why ketamine for depression is usually self-pay.
| What you are comparing | Spravato (esketamine) | Ketamine (off-label) |
|---|---|---|
| FDA status | Approved for treatment-resistant depression in adults, alone or with an oral antidepressant | Not approved for depression at any route, used off-label |
| Where it is given | A REMS-certified setting, with at least two hours of monitoring after each dose | In office, under clinical monitoring. At WBMA it is an intramuscular injection, not an infusion |
| Usual coverage path | Runs through the plan’s benefit, almost always behind prior authorization. At WBMA that route goes through BMS.care | Rarely covered, typically self-pay |
| What patients pay | Depends entirely on your plan, your deductible, and your cost share | $400 per intramuscular session at WBMA, monitoring included. A 2020 published estimate puts infusions elsewhere at $500 to $1,000 |
| Ask about this first | Whether your plan lists it, and how many prior medications must have failed | The full course price in writing, not the single-session price |
What Ketamine Therapy Costs Without Insurance
Published work puts ketamine infusions at $500 to $1,000 per treatment when patients pay out of pocket. That figure comes from a 2020 analysis in the Journal of Managed Care & Specialty Pharmacy. You can read the original cost analysis directly rather than taking anyone’s summary of it.
One detail matters before you use that number. It describes intravenous infusions, and WBMA does not offer IV ketamine. Our ketamine route is an intramuscular injection, given in office under clinical monitoring, and a session here is $400 with the monitoring included. The published infusion figure is background for the category, not a price for what happens at this practice.
Treat that as a national reference point and nothing more. The number is six years old. It predates recent changes in how these treatments are delivered and priced, and it says nothing about what any particular practice charges today. Nobody should walk into a consultation quoting it as an expected bill.
Two things make a per-session number misleading on its own. Ketamine for depression is given as a course rather than a single visit, so the figure that decides your budget is the course total. And prices move with the city, the setting, and whether you are looking at a psychiatric practice or a standalone infusion clinic.
A number in an article is a reference point, never a quote. Ask whichever practice you are considering for the full course cost in writing. That figure should cover the evaluation, every session in the initial course, and any maintenance dosing afterward. A verbal estimate has a way of shifting by the time the first bill arrives.
If cost is what decides this rather than clinical fit, say that out loud at the consultation. Sometimes the better answer is a different treatment. TMS and ketamine differ on coverage as much as they differ clinically, and TMS is FDA-cleared for depression, which changes the insurance conversation completely.
How to Get Ketamine Therapy Covered by Insurance
For Spravato, the route runs through prior authorization, and what your plan asks for is not standardized. A 2024 study in Clinical Therapeutics reviewed esketamine coverage policies from 18 large commercial health plans in the United States and found the requirements differed plan to plan.
For treatment-resistant depression, plans required patients to have already failed somewhere between one and five prior treatments before granting access. They also disagreed about which specific therapies had to be tried first, and about the symptom-severity thresholds and rating scales used to judge who qualifies. The full coverage-variation study lays out the comparison.
Plan-by-plan variation is the real answer to what insurance covers ketamine therapy. There is no national rule to look up. There is your plan’s policy, and it can differ from your neighbor’s plan on the same drug for the same diagnosis.
What tends to move an authorization forward is documentation. Your psychiatrist needs a record of which antidepressants you tried, at what dose, for how long, and what happened on each one. A vague medication history is the most common reason a request stalls, and it is the part you can prepare before your first appointment.
Our page on Spravato dosing and what sessions involve covers the treatment schedule and the monitoring requirement, which is the other half of what a plan reviewer examines. Bring both pieces to the appointment, your medication history and a clear sense of the schedule you are agreeing to. It shortens the back and forth considerably.
What Out-of-Network Means Here, and Where Insurance Still Works
Is ketamine therapy covered by insurance when the practice itself sits outside your network? Those are two separate questions, and running them together is where most of the confusion starts. One is about the drug. The other is about who sends you the bill.
WBMA is an out-of-network specialty practice and does not bill insurance directly. That sentence ends the conversation for some readers, so it is worth being specific about what it means for your wallet. The phrase sounds like a closed door. In practice it describes a different payment sequence, not the absence of one.
BMS.care is where the insurance route lives. Brain Modulation Services is the in-network arm of the same practice family, and it delivers Spravato and TMS under insurance. It works with Cigna, Aetna, Blue Cross Blue Shield and United Healthcare. Call your own plan to confirm your benefits before you count on any of it.
For anything that stays at WBMA, you pay the practice at the time of service. If your plan carries out-of-network benefits, you may then be reimbursed for part of what you paid, at whatever rate your plan has set. Some plans reimburse a meaningful share. Some reimburse nothing at all.
Prior authorization on the Spravato benefit is a separate track from a practice’s network status, and our team helps with that regardless. Being out of network does not take that support off the table. An authorization decides whether your plan will pay for the drug at all. Network status only decides how the practice’s own fee reaches you.
There is also a wider set of options around the practice. WBMA’s care ecosystem and access options sets out which affiliated organizations accept insurance, which run sponsored research studies at no out-of-pocket cost to qualifying participants, and which offer low-cost care. If out-of-network is a hard stop for you financially, start there rather than dropping the idea of treatment.
Questions to Ask Your Insurer Before You Book
Call the member services number on the back of your card. These are the questions that produce an answer you can act on. Write down every answer, along with the date and the name of the representative who gave it. Plans change their positions, and a dated note is the only thing that survives that.
Your seven-question benefits call
- Is esketamine covered under my plan, and under which benefit does it fall
- How many prior antidepressants must have failed before you will approve it
- Which specific medications count toward that requirement
- What is my cost share once it is approved, including deductible and coinsurance
- Do you require a particular rating-scale score, and which scale do you use
- What are my out-of-network benefits for psychiatric care, and what percentage do you reimburse
- How long does an approval last before it has to be renewed
Ask about ketamine separately, and ask it as its own question. Some representatives answer about esketamine and let you assume the answer covers both, which is how patients end up surprised by a bill. Say the word ketamine on its own, and name the route you are being offered, so the answer you get is about the right treatment.
Frequently Asked Questions
Is ketamine therapy covered by insurance when my depression has not responded to medication?
Treatment-resistant depression is exactly what Spravato is approved for, so you are in the strongest position a patient can be in with a plan. Coverage still depends on your specific policy and on prior authorization, and published research shows plans set that bar anywhere from one to five failed treatments.
Why does insurance cover Spravato but not ketamine?
Spravato holds an FDA approval for treatment-resistant depression. Ketamine is used off-label for depression, whatever route it is given by. Plans generally do not pay for off-label use of a generic anesthetic, however reasonable the clinical rationale is. The approval, not the evidence base, is what the billing system responds to.
How much is ketamine therapy out of pocket?
At WBMA an intramuscular ketamine session is $400, monitoring included, and it is self-pay. For context, one published estimate from 2020 put ketamine infusions at $500 to $1,000 per treatment, though WBMA does not offer infusions. Because ketamine is given as a course, ask for the total across the full course and get it in writing.
Does WBMA offer IV ketamine infusions?
No. Ketamine at WBMA is given as an intramuscular injection, in office and under clinical monitoring. It is the same medication and the same off-label status as an infusion, so the coverage answer does not change. If a specific route matters for your care, raise it at the consultation.
What insurance covers ketamine therapy?
There is no fixed list. A 2024 review of 18 large commercial plans found each one set its own access criteria for esketamine. The only reliable answer comes from calling your own plan and asking what it requires. A friend’s experience with a different carrier tells you almost nothing about yours.
Does WBMA take insurance for ketamine therapy?
WBMA is out-of-network and does not bill insurance directly, so ketamine here is self-pay. Spravato is the different case. It can be delivered through your insurance at BMS.care, the in-network practice affiliated with WBMA, which works with Cigna, Aetna, Blue Cross Blue Shield and United Healthcare. Confirm what your own plan pays before you assume.
How long does insurance approval take?
It varies by plan and by how complete the submitted documentation is. The single thing most within your control is having a clear record of prior medications, doses, and durations ready before your evaluation. Incomplete histories are what send a request back for more information, and that round trip costs weeks.
What happens if my prior authorization is denied?
A denial is not automatically the end of it. Plans have an appeals process, and your psychiatrist can often request a peer-to-peer review with the plan’s reviewing physician. Ask what specific criterion the denial cited, because that is what an appeal has to address.
Where to Start
Is ketamine therapy covered by insurance in your particular case? If two or more antidepressants have not given you relief, that question is worth settling before it turns into a reason to wait. A consultation reviews your medication history, tells you whether Spravato or ketamine fits your situation, and shows you which payment route applies to each.
Start a ketamine and Spravato consultation at WBMA
The $400 session figure is WBMA’s current self-pay rate for an intramuscular ketamine session and is not a quote for a full course of treatment. Other dollar figures cited here come from published third-party research and are national reference points. Coverage varies by plan and by carrier.
